Published May 25, 2023
| Version v1
Journal article
Open
ANALYSIS OF THE DYNAMICS OF TREATMENT OF INFILTRATIVE TUBERCULOSIS WITH DRUGS OF THE 5TH LINE. 1 TRIMESTER
Authors/Creators
- 1. Doctor - phthisiatrician of the 1st category of the 2nd therapeutic department of the KSE "Kostanay Regional Center for Phthisiopulmonology"(Kostanay, Kazakhstan)
- 2. Doctor - phthisiatrician of the 2nd therapeutic department of the KSE "Kostanay regional center of phthisiopulmonology"(Kostanay, Kazakhstan)
- 3. Doctor - phthisiatrician of the 2nd therapeutic department of the KSE "Kos Sazanova tanay regional center of phthisiopulmonology" (Kostanay, Kazakhstan)
- 4. Doctor - phthisiatrician of the 2nd therapeutic department of the KSE "Kostanay regional center of phthisiopulmonology" (Kostanay, Kazakhstan)
- 5. Candidate of Philology, Associate Professor of the Department of Humanities, Kostanay Socio-Technical University named after Academician Z. Aldamzhar (Kostanay, Kazakhstan)
- 6. Head of the 2nd therapeutic department of the KSE "Kostanay regional center of phthisiopulmonology", doctor - phthisiopulmonology of the highest category (Kostanay, Kazakhstan)
Description
Abstract
This article analyzes the dynamics of the treatment of infiltrative tuberculosis with drugs of the 5th line. 1 trimester
Notes
References:
1. Bogadelnikova I.V., Perelman M.I. (1997) Antibacterial therapy of pulmonary tuberculosis. Universum Publishing, Moscow, 80 p.
2. Bone A. (2001) Tuberculosis and HIV/AIDS. In: P. Bollini (ed.) HIV in prisons. Prakt. allowance (for penitentiary systems of the New Independent States). European Office of the World Health Organization, Copenhagen (http://www.afew.org/russian/prisons_articles/14-8prisoners.php).
3. Zmushko E.I., Belozerov E.S. (2001) Medical complications. Peter, St. Petersburg, 448 p.
4. Koshechkin V.A., Ivanova Z.A. Tuberculosis: Tuberculosis: A Study Guide. M.: Publishing House of RUDN University, 2006. S. 190-210.
5. Mishin V.Yu., Chukanova V.I., Grigoriev Yu.G. Side effects of anti-tuberculosis drugs in standard and individualized chemotherapy regimens. Moscow: Computerburg Publishing House, 2004, p. 208.
6. Ministry of Health of Ukraine (2006) Approval of the Protocol on the provision of medical assistance to people who are ill for tuberculosis. Order of the Ministry of Health of Ukraine No. 384 dated 09.06.2006 (http://www.moz.gov.ua/ua/main/docs/?docID=6270).
7. Polunina T.E. (2005) Drug-induced liver injury. Attending Physician, 3:69–72.
8. Rafalsky V.V. (2000) Adverse drug reactions and interactions in antibiotic therapy for urinary tract infections. RMJ, 8(3): 110–116.
9. Rakhimov K.D., Palgova L.K., Alenova A.Kh., Zordinova K.A., Kurmanova B.S. (2004) Handbook of side effects of drugs. Almaty, 224 p.
10. Skakun M.N., Posokhova K.A. (2003) Pharmacology: Pdruchnik. Ukrmedkniga, Ternopil, 740 p.
11. Strachunsky L.S., Kozlov S.N. (2001) Modern antimicrobial chemotherapy. Borges, Moscow, 432 p.
12. Feshchenko Yu.I., Cherenko S.A. (2007) Domestic phthisiology today: based on the results of the workshop. Health of Ukraine, 2/1: 11–12.
13. Feshchenko Yu.I. (2008) Propositions for better tuberculosis control in Ukraine. Update on awards at the Ministry of Health of Ukraine on February 7, 2008 (http://www.ifp.kiev.ua/doc/staff/feschenko2008.pdf).
14. Kharkevich D.A. (2004) Pharmacology: A textbook for universities. 8th ed., revised, additional. and correct. Geotar-Media, Moscow, 736 p.
15. Harris E, Maher D, Graham S (2004) TB/HIV. Clinical guide. 2nd ed. World Health Organization, Geneva, 224 p. (http://whqlibdoc.who.int/publications/2005/9244546345_rus.pdf).
16. Chukanov V.I. (2001) The problem of curing patients with respiratory tuberculosis. RMJ, 9(21): 954–959.
17. Chukanov V.I., Kaminskaya G.O., Livchane E. (2004) The frequency and nature of adverse reactions in the treatment of patients with pulmonary tuberculosis with reserve anti-tuberculosis drugs. Problems of Tuberculosis and Lung Diseases, 10: 6–10.
18. Shapoval O.N. (2005) Problems and perspectives of tuberculosis treatment. Provisor, 20: http://www.provisor.com.ua/archive/2005/N20/art_33.htm.
19. British Medical Association Royal Pharmaceutical Society of Great Britain (2004) British National Formulary 48. London, 902 p.
20. Chen L., Liang Y. (1999) Optic nerve neuropathy by ethambutol toxicity. Zhonghua Jie He He Hu Xi Za Zhi, 22(5): 302–304.
21. Citron K.M., Thomas G.O. (1986) Ocular toxicity from ethambutol. Thorax, 41(10): 737–739.
22. Kahana L.M. (1987) Toxic ocular effects of ethambutol. C.M.A.J., 137(3): 213–216.
23. Mandell G.L., Sande M.A. (1990) Antimicrobial Agents: Drugs Used in the Chemotherapy of Tuberculosis and Leprosy. In: A.G. Gilman, T.W. Rall, A.S. Nies, P. Taylor (Eds.): The Pharmacological Basis of Therapeutics. 8th Ed., Pergamon Press, New York, p. 1146–1164.
24. Shindler K.S., Zurakowski D., Dreyer E.B. (2000) Caspase inhibitors block zinc-chelator induced death of retinal ganglion cells. Neuroreport, 11(10): 2299–2302.
25. The Tuberculosis Control Coordinating Committee (Department of Health) and the Tuberculosis Subcommittee of the Coordinating Committee in Internal Medicine (Hospital Authority), Hong Kong (1998) Chemotherapy of tuberculosis in Hong Kong: a consensus statement. Hong Kong Med. J., 4(3): 315–320.
26. World Health Organization (2003) Treatment of tuberculosis: guidelines for national programs (Third edition). WHO, Geneva, 108p (http://www.who.int/tb/publications/cds_tb_2003_313/en/).
27. Yoon Y.H., Jung K.H., Sadun A.A., Shin H.C., Koh J.Y. (2000) Ethambutol-induced vacuolar changes and neuronal loss in rat retinal cell culture: mediation by endogenous zinc. Toxicol. Appl. Pharmacol., 162(2): 107-114.